IBCL - 1506
Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect of Epcoritamab (E) With Lenalidomide and Rituximab (R2) in Relapsed/Refractory Follicular Lymphoma (R/R FL)
Bradley Hunter
Poster Presenter: Bradley Hunter
